Published in Medical Letter on the CDC and FDA, September 6th, 2009
Extavia is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging (MRI)(4).
Keywords: Novartis Pharmaceuticals Corporation, U.S. Food and Drug Administration, FDA, Neurology, Neuroimmunology,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA